Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2169)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 26.04.24 23:20:55 von
neuester Beitrag 26.04.24 23:20:55 von
Beiträge: 22.815
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 4
Gesamt: 1.231.719
Gesamt: 1.231.719
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVAX
3,8085
EUR
+3,58 %
+0,1315 EUR
Letzter Kurs 26.04.24 Tradegate
Neuigkeiten
20.04.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 7,3500 | +43,84 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Das Warten Spiel zerschlagen Novavax, Inc. im März, Versand von Aktien nach unten 15%
Die Bargeldrate des Unternehmens ist ein ernstes Anliegen.
https://www.fool.com/investing/2017/04/05/the-waiting-game-c…
LG tz
Die Bargeldrate des Unternehmens ist ein ernstes Anliegen.
https://www.fool.com/investing/2017/04/05/the-waiting-game-c…
LG tz
Novavax: 'We still expect to enjoy the advantage of being the first RSV vaccine'
Feb 28, 2017, 7:10am EST Updated Feb 28, 2017, 10:10am EST
Gaithersburg-based Novavax executives still believe their company is leading the race to produce a vaccine against respiratory syncytial virus, or RSV, they told investors during a Monday earnings call.
Novavax (NASDAQ: NVAX) recently opened a phase 2 clinical trial to begin retesting its previous lead vaccine candidate for elderly patients after suffering a devastating failed phase 3 clinical trial in September. RSV is the most common cause of pneumonia and inflammation of the small airways in lungs in children under 1. It impacts other age groups as well.
They expect results back by the third quarter.
At the same time, Novavax has redirected its focus into a phase 3 clinical trial for an RSV vaccine for infants via maternal immunization. The company is in discussions with the U.S. Food and Drug Administration over whether it can begin an informational analysis of that vaccine candidate's efficacy, officials said. That would enable to company to begin preparing for commercialization.
“We continue to believe there is a multi-billion opportunity for our RSV-F franchise and we still expect to enjoy the advantage of being the first RSV vaccine to market,” Novavax President and CEO Stanley Erck said.
Other companies working on RSV vaccines include Gaithersburg-based MedImmune, which is the research and development arm for AstraZeneca, and GlaxoSmithKline.
Novavax reported a net loss $57.1 million during the fourth quarter, surpassing some analysts expectations. It was an improvement over the same quarter in 2015, when it reported a net loss of $78.8 million.
The company reported a loss of $280 million for 2016, compared to a net loss of $156.9 million in 2015. Revenue was less than half it was in 2015 — $15.4 million compared to $36.3 million. Officials blamed the decrease in revenue on the expiration of a federal contract and said the funding was partially offset by funding from the Bill and Melinda Gates Foundation. Novavax is supported by an $89 million grant from the Gates Foundation for its efforts to create an RSV vaccine for infants.
Novavax is also working to create a vaccine candidate for Zika with a goal of beginning a Phase 1 trial later this year. On Monday, Erck told analysts he believes the U.S. will continue to prioritize Zika because of its devastating effects on pregnancies.
http://www.bizjournals.com/washington/news/2017/02/28/novava…
Ich hatte nach den Zahlen eigentlich Kurse unter 1,40$ erwartet, aber ist ja gut so.
Feb 28, 2017, 7:10am EST Updated Feb 28, 2017, 10:10am EST
Gaithersburg-based Novavax executives still believe their company is leading the race to produce a vaccine against respiratory syncytial virus, or RSV, they told investors during a Monday earnings call.
Novavax (NASDAQ: NVAX) recently opened a phase 2 clinical trial to begin retesting its previous lead vaccine candidate for elderly patients after suffering a devastating failed phase 3 clinical trial in September. RSV is the most common cause of pneumonia and inflammation of the small airways in lungs in children under 1. It impacts other age groups as well.
They expect results back by the third quarter.
At the same time, Novavax has redirected its focus into a phase 3 clinical trial for an RSV vaccine for infants via maternal immunization. The company is in discussions with the U.S. Food and Drug Administration over whether it can begin an informational analysis of that vaccine candidate's efficacy, officials said. That would enable to company to begin preparing for commercialization.
“We continue to believe there is a multi-billion opportunity for our RSV-F franchise and we still expect to enjoy the advantage of being the first RSV vaccine to market,” Novavax President and CEO Stanley Erck said.
Other companies working on RSV vaccines include Gaithersburg-based MedImmune, which is the research and development arm for AstraZeneca, and GlaxoSmithKline.
Novavax reported a net loss $57.1 million during the fourth quarter, surpassing some analysts expectations. It was an improvement over the same quarter in 2015, when it reported a net loss of $78.8 million.
The company reported a loss of $280 million for 2016, compared to a net loss of $156.9 million in 2015. Revenue was less than half it was in 2015 — $15.4 million compared to $36.3 million. Officials blamed the decrease in revenue on the expiration of a federal contract and said the funding was partially offset by funding from the Bill and Melinda Gates Foundation. Novavax is supported by an $89 million grant from the Gates Foundation for its efforts to create an RSV vaccine for infants.
Novavax is also working to create a vaccine candidate for Zika with a goal of beginning a Phase 1 trial later this year. On Monday, Erck told analysts he believes the U.S. will continue to prioritize Zika because of its devastating effects on pregnancies.
http://www.bizjournals.com/washington/news/2017/02/28/novava…
Ich hatte nach den Zahlen eigentlich Kurse unter 1,40$ erwartet, aber ist ja gut so.
...bin heute morgen auch mal auf Verdacht rein...
könnte was werden. Bin auch am überlegen. Der Rebound könnte aber auch noch etwas dauern, so er denn kommt
Ich bin mal wieder mit einer ersten Position hier rein. Der Anstieg gestern sah schon gut aus, schönes Volumen und fast auf Tageshoch geschlossen.
Trading Spotlight
Sieht derzeit Verlockend aus.
Antwort auf Beitrag Nr.: 53.575.341 von question-mark am 28.10.16 16:00:33Ich hab leider auch die Befürchtung und warte aber das Update vom 09.11.16 noch ab.
Antwort auf Beitrag Nr.: 53.429.925 von DasTier666 am 07.10.16 14:11:27jetzt ist sie durchbrochen, mal sehen wo es hingeht, vielleicht auf das low vom Absturz?
Antwort auf Beitrag Nr.: 53.429.925 von DasTier666 am 07.10.16 14:11:27die 1,50 könnte gleich dahin sein
Novavax Reschedules 4th Annual Investor and Analyst Meeting
Oct 07, 2016
...The Company will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016.
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-news&nyo=…
na super, hoffentlich hält die 1,50$ bis dahin.
Oct 07, 2016
...The Company will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016.
http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-news&nyo=…
na super, hoffentlich hält die 1,50$ bis dahin.
Durchsuchen
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |